332 related articles for article (PubMed ID: 30338644)
1. Anti-tumor necrosis factor biosimilars and intended copies in rheumatology: Perspective from the Asia Pacific region.
Rath PD; Chen DY; Gu J; Lee VWY; Al Ani NA; Shirazy K; Llamado L
Int J Rheum Dis; 2019 Jan; 22(1):9-24. PubMed ID: 30338644
[TBL] [Abstract][Full Text] [Related]
2. Clinical and regulatory perspectives on biosimilar therapies and intended copies of biologics in rheumatology.
Mysler E; Pineda C; Horiuchi T; Singh E; Mahgoub E; Coindreau J; Jacobs I
Rheumatol Int; 2016 May; 36(5):613-25. PubMed ID: 26920148
[TBL] [Abstract][Full Text] [Related]
3. Biosimilars in rheumatology: recommendations for regulation and use in Middle Eastern countries.
El Zorkany B; Al Ani N; Al Emadi S; Al Saleh J; Uthman I; El Dershaby Y; Mounir M; Al Moallim H
Clin Rheumatol; 2018 May; 37(5):1143-1152. PubMed ID: 29411181
[TBL] [Abstract][Full Text] [Related]
4. Use of Biologics and Biosimilars in Rheumatology.
Sharma SK
J Assoc Physicians India; 2017 May; 65(5 Suppl):9-14. PubMed ID: 28836745
[TBL] [Abstract][Full Text] [Related]
5. [Evolution of biologicals in inflammation medicine--biosimilars in gastroenterology, rheumatology and dermatology].
Schreiber S; Luger T; Mittendorf T; Mrowietz U; Müller-Ladner U; Schröder J; Stallmach A; Bokemeyer B
Dtsch Med Wochenschr; 2014 Nov; 139(47):2399-404. PubMed ID: 25390629
[TBL] [Abstract][Full Text] [Related]
6. Similar and mimics: Latin America biosimilar regulations.
Lizarraga A; Mysler E
Int J Rheum Dis; 2019 Jan; 22(1):6-8. PubMed ID: 30689310
[No Abstract] [Full Text] [Related]
7. Biosimilars in rheumatology: A review of the evidence and their place in the treatment algorithm.
Schulze-Koops H; Skapenko A
Rheumatology (Oxford); 2017 Aug; 56(suppl_4):iv30-iv48. PubMed ID: 28903543
[TBL] [Abstract][Full Text] [Related]
8. Practical Guidance on Biosimilars, With a Focus on Latin America: What Do Rheumatologists Need to Know?
Azevedo VF; Babini A; Caballero-Uribe CV; Castañeda-Hernández G; Borlenghi C; Jones HE
J Clin Rheumatol; 2019 Mar; 25(2):91-100. PubMed ID: 30059414
[TBL] [Abstract][Full Text] [Related]
9. Biosimilar monoclonal antibodies: preclinical and clinical development aspects.
Gonçalves J; Araújo F; Cutolo M; Fonseca JE
Clin Exp Rheumatol; 2016; 34(4):698-705. PubMed ID: 27383278
[TBL] [Abstract][Full Text] [Related]
10. Current state of biosimilars in Mexico: The position of the Mexican College of Rheumatology, 2016.
Xibille D; Carrillo S; Huerta-Sil G; Hernández R; Limón L; Olvera-Soto G; Jara-Quezada LJ; Esquivel A; Pérez-Rodríguez M
Reumatol Clin (Engl Ed); 2018; 14(3):127-136. PubMed ID: 28807650
[TBL] [Abstract][Full Text] [Related]
11. [Biosimilars in rheumatology. Development and results of clinical trials].
Alten R
Z Rheumatol; 2015 Oct; 74(8):682-8. PubMed ID: 26347121
[TBL] [Abstract][Full Text] [Related]
12. PANLAR consensus statement on biosimilars.
Kowalski SC; Benavides JA; Roa PAB; Galarza-Maldonado C; Caballero-Uribe CV; Soriano ER; Pineda C; Azevedo VF; Avila-Pedretti G; Babini AM; Cachafeiro-Vilar A; Cifuentes-Alvarado M; Cohen SB; Díaz PE; Soto LD; Encalada C; Garro B; Sariego IAG; Guibert-Toledano M; Rodriguez VJK; Lopez MEL; Ortega AP; Russell AS; Santos-Moreno P; Terán IS; Vargas A; Vásquez G; Xavier RM; Firedman DXX; Mysler E; Kay J
Clin Rheumatol; 2019 May; 38(5):1485-1496. PubMed ID: 30915652
[TBL] [Abstract][Full Text] [Related]
13. Position paper of Italian rheumatologists on the use of biosimilar drugs.
Atzeni F; Sebastiani M; Ricci C; Celano A; Gremese E; Iannone F; Meroni PL; Minghetti P; Sarzi-Puttini P; Ferraccioli G; Lapadula G
Clin Exp Rheumatol; 2015; 33(1):1-4. PubMed ID: 25436597
[TBL] [Abstract][Full Text] [Related]
14. The changing landscape of biosimilars in rheumatology.
Dörner T; Strand V; Cornes P; Gonçalves J; Gulácsi L; Kay J; Kvien TK; Smolen J; Tanaka Y; Burmester GR
Ann Rheum Dis; 2016 Jun; 75(6):974-82. PubMed ID: 26964144
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety Outcomes for Originator TNF Inhibitors and Biosimilars in Rheumatoid Arthritis and Psoriasis Trials: A Systematic Literature Review.
Moots RJ; Curiale C; Petersel D; Rolland C; Jones H; Mysler E
BioDrugs; 2018 Jun; 32(3):193-199. PubMed ID: 29790131
[TBL] [Abstract][Full Text] [Related]
16. Efficacy, safety and pharmacokinetics of biosimilars of anti-tumor necrosis factor-α agents in rheumatic diseases; A systematic review and meta-analysis.
Komaki Y; Yamada A; Komaki F; Kudaravalli P; Micic D; Ido A; Sakuraba A
J Autoimmun; 2017 May; 79():4-16. PubMed ID: 28209290
[TBL] [Abstract][Full Text] [Related]
17. Biosimilars in rheumatology.
Araújo FC; Gonçalves J; Fonseca JE
Pharmacol Res; 2019 Nov; 149():104467. PubMed ID: 31568820
[TBL] [Abstract][Full Text] [Related]
18. Biosimilars in pediatric rheumatology and their introduction into routine care.
Aragon Cuevas O; Hedrich CM
Clin Immunol; 2020 Jul; 216():108447. PubMed ID: 32360950
[TBL] [Abstract][Full Text] [Related]
19. Era of biosimilars in rheumatology: reshaping the healthcare environment.
Smolen JS; Goncalves J; Quinn M; Benedetti F; Lee JY
RMD Open; 2019; 5(1):e000900. PubMed ID: 31245050
[TBL] [Abstract][Full Text] [Related]
20. Update on biosimilars in rheumatology.
Rischin A; Östör AJ
Inflammopharmacology; 2017 Apr; 25(2):177-184. PubMed ID: 28265837
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
